ArticleCancer science2018
Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients.
Article in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- The clinical picture of Castleman disease: a systematic review and meta-analysis.Blood advances · 2024Pooled it
- A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.International journal of hematology · 2024Trial
- Hyperenhancing paravertebral mass in an adolescent: A rare presentation of unicentric Castleman disease.Radiology case reports · 2026Article
- Complete Resection of a Giant Middle Mediastinal Castleman Disease Using Robot-Assisted Thoracic Surgery: A Case Report.Surgical case reports · 2026Article
- The sonographic characteristics of unicentric castleman disease - a single-center retrospective study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Idiopathic multicentric Castleman disease in children: a single-center retrospective analysis.BMC pediatrics · 2025Article
- A case report of Castleman disease variant of POEMS syndrome presenting with prominent polyserositis and renal impairment.Frontiers in medicine · 2025Article
- Prognostic value of serum C-reactive protein in idiopathic multicentric Castleman disease and construction of a prognostic model for patients.Frontiers in medicine · 2025Article
- Successful Treatment of Idiopathic Multicentric Castleman Disease With Rash as the Initial Symptom Using a Rituximab-Based Regimen.Journal of hematology · 2024Article
- Abdominal CT findings characteristic of Castleman disease: multi-centre review of 76 adult cases with abdominopelvic nodal involvement.The British journal of radiology · 2024Article
- Multicentric Castleman disease of hyaline‑vascular variant with paraneoplastic pemphigus results in abnormal lung function: Report of 3 cases.Experimental and therapeutic medicine · 2023Article
- Exploring Castleman disease in China: pre-IL-6 treatment era and advancements in knowledge.The Lancet regional health. Western Pacific · 2023Article
- A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.The Lancet regional health. Western Pacific · 2023Article
- An unexpected case of Castleman disease in porta hepatis lymphadenopathy.Journal of surgical case reports · 2023Article
- Analysis of characteristics of four patients with adrenal unicentric Castleman disease.Frontiers in endocrinology · 2023Article
- [The clinical features of Castleman disease in the head and neck].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2022Article
- The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.British journal of haematology · 2022Article
- Castleman disease of the pancreas mimicking pancreatic malignancy onWorld journal of gastrointestinal surgery · 2022Article
- Comprehensive analysis of 65 patients with Castleman disease in a single center in China.Scientific reports · 2022Article
- Clinical characteristics and prognosis of patients with Castleman disease in a Chinese hospital: paraneoplastic pemphigus is an independent risk factor.American journal of translational research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castleman disease (CD) is a rare lymphoproliferative disorder. To assess the clinical features, outcomes, and prognostic factors of this disease, we retrospectively analyzed 185 HIV-negative CD patients from four medical centers in southern China. The median age was 37 years. One hundred and twenty-one patients (65.4%) were classified as unicentric CD (UCD) and 64 patients (34.6%) were classified as multicentric CD (MCD). The histology subtype was hyaline-vascular for 132 patients (71.4%), plasma cell for 50 patients (27%), and mixed type for 3 patients (1.6%). The 5-year overall survival (OS) of 185 CD cases was 80.3%. All UCD patients underwent surgical excision, whereas the treatment strategies of MCD patients were heterogeneous. The outcome for UCD patients was better than MCD patients, with 5-year OS rates of 93.6% and 51.2%, respectively. In further analysis of the MCD subgroup, a multivariate analysis using a Cox regression model revealed that age, splenomegaly and pretreatment serum albumin level were independent prognostic factors for OS. This multicenter study comprising the largest sample size to date suggested that MCD is a distinct entity from UCD with a significantly worse outcome. Older age (≥40 years), splenomegaly, and hypoalbuminemia were risk factors for poorer MCD prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.